MedWatch

Biotech beats the general market in the long run

Over the last couple of decades a large number of Biotech-companies have closed down, but the relatively few market winners have done so well that the Biopharma-index triumphs over the general market.

Foto: JP-Grafik: GG, RK

Despite the fact that investors are getting rid of biotech-shares as the general willingness to take risks is dropping off, the American Biotech-index has completely outperformed the general industry-index over a period of 17 years.

This can be seen in the growth of the AMEX Biotechnology Index, and it is a development that major investor Florian Schönharting recognizes from the global biotech market - a market where several major companies – such as Novo Nordisk among others – produce pharmaceuticals and have turnovers in the billions.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier